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Although ErbB receptors have been implicated in the progression of prostate cancer, little is known about proteins that may mediate
their interactions with the androgen receptor (AR). Ebp1, a protein cloned via its association with the ErbB3 receptor, binds the AR
and inhibits androgen-regulated transactivation of wild-type AR in COS cells. As the complement of coregulators in different cells are
important for AR activity, we determined the effect of Ebp1 on AR function in prostate cancer cell lines. In addition, we examined the
regulation of Ebp1 function by the ErbB3/4 ligand heregulin (HRG). In this study, we demonstrate, using several natural AR-regulated
promoters, that Ebp1 repressed transcriptional activation of wild-type AR in prostate cancer cell lines. Downregulation of Ebp1
expression in LNCaP cells using siRNA resulted in activation of AR in the absence of androgen. Ebp1 associated with ErbB3 in LNCaP
cells in the absence of HRG, but HRG induced the dissociation of Ebp1 from ErbB3. In contrast, HRG treatment enhanced both the
association of Ebp1 with AR and also the ability of Ebp1 to repress AR transactivation. These studies suggest that Ebp1 is an AR
corepressor whose biological activity can be regulated by the ErbB3 ligand, HRG.
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Prostate cancer is the second most prevalent cancer among men in
the United States and ranks second to lung cancer in terms of
annual mortality (Weir et al, 2003). Prostate cancer begins as an
androgen-dependent tumour that undergoes clinical regression in
response to pharmacological and surgical strategies that reduce
testosterone concentration. Despite this treatment, the cancer
eventually regrows as an androgen- or hormone-independent
tumour (Feldman and Feldman, 2001). Microarray analysis of both
androgen dependent and independent tumour xenografts (Amler
et al, 2000; Mousses et al, 2001) and human prostate cancer
samples (LaTulippe et al, 2002) during disease progression has
identified several candidate targets, including the AR itself, for
prostate cancer therapy and diagnosis associated with the
androgen independent phenotype. Thus, aberrant changes in AR
signalling are likely to play a role in the progression to androgen
independence (Grossmann et al, 2001). Chen et al (2004) showed,
using microarray-based profiling of isogenic prostate cancer
xenografts, that increases in AR mRNA were the only changes
consistently associated with development of resistance to anti-
androgen therapy, providing a strong rationale for targeting the
downregulation of androgen receptor (AR) activity in the
treatment of advanced prostate cancer.
The potential role of the epidermal growth factor (ErbB) family
of receptors and their ligands in regulating AR activity during
prostate cancer progression is currently a focus of intense
investigation. This receptor family includes four members: EGFR
(ErbB1), ErbB2 (Neu, HER2), ErbB3 (Her3) and ErbB4 (Her4). All
EGFR family members contain an extracellular ligand binding
domain, a transmembrane region important in regulating receptor
activity, and a cytoplasmic tyrosine kinase domain. ErbB3 lacks
tyrosine kinase activity due to amino-acid substitutions in the
conserved kinase domain (Kirschbaum and Yarden, 2000). ErbB
receptors have been implicated in the pathogenesis and progres-
sion of many types of human cancers and therapies directed
against these receptors are in clinical use (Yarden, 2001). An
extensive body of work demonstrating cross talk between ErbB
receptors and their ligands and the AR in prostate cancer has
evolved (El Sheikh et al, 2003). For example, the EGF receptor is
overexpressed in both benign prostatic hypertrophy (BPH) and
prostate cancer (De Miguel et al, 1999). EGFR overexpression is
observed in patients during a conversion to androgen independent
growth (Olapade-Olaopa et al, 2000; Hernes et al, 2004). The role
of ErbB2 in rendering cells androgen independent or more
sensitive to extremely low levels of androgen has been demon-
strated both in vitro and in animal models (Craft et al, 1999; Yeh
et al, 1999). ErbB2 is also required for IL-6 activation of AR
signalling (Qiu et al, 1998). However, studies of the role of ErbB2
in clinical prostate cancer remain inconclusive (Grossmann et al,
2001), and initial clinical trials indicate that the anti-ErbB2
antibody Herceptin (trastuzumab) does not show significant
clinical activity as a single agent (Ziada et al, 2004). ErbB3 has
not been as extensively studied, but analysis of clinical prostate
cancer specimens indicates that overexpression of ErbB3 has been
linked to a less favourable prognosis (Leung et al, 1997).
EGF-like ligands have been shown in vitro and in vivo to
stimulate growth of prostate cancer cells. For example, in vitro AR
is activated in a ligand independent manner by EGF (Culig et al,
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s1994). Torring et al (2003) recently showed that LNCaP cells
constitutively express EGF ligands and that ErbB1 activity is
necessary for androgen-induced proliferation. Endogenous stro-
mal derived factors such as Heparin binding-EGF attenuate the
response of AR to its ligands, resulting in androgen independent
growth of LNCaP cells (Adam et al, 2002). By contrast, the ErbB3/4
ligand HRG is highly expressed in basal, luminal and stromal cells
of the normal prostate, but not in prostate tumours (Lyne et al,
1997). Further, HRG protein is not detected in the prostate cancer
cell lines LNCaP, DU-145 or PC-3 (Grasso et al, 1997a; Lyne et al,
1997). HRG mRNA could be detected in these cell lines only by
RT–PCR in one study (Lyne et al, 1997), but was not detected in
another (Grasso et al, 1997a). HRG inhibits growth and induces
differentiation of AR positive, ErbB1–3 positive LNCaP cells, but
has little effect on proliferation of ErbB1–3 positive, AR negative
DU 145 and PC-3 cells (Grasso et al, 1997b; Lyne et al, 1997). In
addition, HRG induces the expression of the tumour suppressor
p53 and the CDK inhibitor p21 in LNCaP cells (Bacus et al, 1996).
Most recently, Tal-Or et al (2003) have demonstrated that HRG
activates ErbB2/3 heterodimers and induces apoptosis of LNCaP
cells. These combined findings suggest that HRG signals may
contribute to growth restriction or differentiation of prostate
epithelia.
Our laboratory has recently demonstrated that a protein Ebp1,
isolated by its binding to HRG’s cognate receptor ErbB3 (Yoo et al,
2000), binds AR in vitro and in vivo (Zhang et al, 2002). Ebp1 is
expressed in both normal prostate epithelial cells and in the
prostate cancer cell lines LNCaP, DU-145 and PC-3 (Xia et al,
2001b). Ectopic expression of ebp1 inhibits ligand-mediated
transcriptional activation of both artificial and natural AR
regulated promoters in COS cells transfected with wild-type AR
and in LNCaP cells that express a mutant AR. The transcription of
the endogenous PSA gene is also decreased in LNCaP cells stably
transfected with Ebp1 (Zhang et al, 2002). However, the effect of
Ebp1 on transactivation of wild-type AR in prostate cancer cells
was not established. The purpose of the present study was to
extend our finding that Ebp1 represses AR transactivation and to
determine if the ErbB3 ligand, HRG, affects Ebp1’s interactions
with AR.
MATERIALS AND METHODS
Cell culture
All cell lines except PC-3 AR were obtained from the American
Type Culture Collection (Manassas, VA, USA). PC-3 AR cells
(Long et al, 2000) were a gift of Dr Angela Brodie. Cells were
maintained at 371C in a humidified atmosphere of 5% CO2 in air.
Cell lines were routinely cultured in RPMI 1640 media supple-
mented with 10% foetal bovine serum (FBS) (Sigma, St Louis, MO,
USA).
Plasmids
The PSA reporter luciferase construct was a gift from Dr Martin
Gleave and contains  630/þ12 of the 50 PSA flanking region. The
Probasin ( 285/þ32) luciferase reporter and the pSG5-hAR
expression construct were gifts of Dr O Janne. The MMTV-
luciferase plasmid was obtained from Dr Joseph Fondell (Wang
and Fondell, 2001). The ebp1 expression construct has been
previous described (Xia et al, 2001a).
Immunoprecipitation, GST-pulldowns and Western blot
analysis
To measure ErbB3–Ebp1 interactions, LNCaP cells were incubated
overnight in serum-free RPMI-1640 media. Where indicated, cells
were treated with 20ngml
 1 of HRG b1 (R&D Systems, Mpls, MN,
USA) for the indicated times. Cell lysates were prepared and
immunoprecipitated as described previously (Fernandes et al,
1999). Briefly, cells were lysed with buffer containing 50mM
HEPES (pH 7.5), 1mM EDTA, 150mM NaCl, 1% Triton X-100
and Completet protease inhibitor. Protein concentrations were
measured using a detergent compatible kit (BioRad, Hercules, CA,
USA). Cell lysates were precleared with Protein A/Protein G
agarose and immunoprecipitated for 4h at 41C with 2mgo fa
monoclonal antibody directed against ErbB3 (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) and 20ml packed Protein A/G
agarose beads. The immunoprecipitates were washed and resus-
pended in Laemmli sample buffer. Proteins were resolved by SDS–
PAGE. After electrophoresis, the proteins were transferred onto
Immobilin-P membranes, and immunoblotted as described (Xia
et al, 2001b) using a monoclonal antibody to ErbB3 (Santa Cruz)
or a rabbit polyclonal antibody that detects both phosphorylated
and unphosphorylated forms of Ebp1 (Xia et al, 2001b) (Upstate,
Lake Placid, NY, USA). To measure the association of endogenous
AR and endogenous Ebp1, LNCaP cells, growing in complete
media, were switched to phenol-red free RPMI 1640 containing 1%
charcoal stripped calf serum (CSS) (Sigma) and 10
 8 M R1881
(NEN, Boston, MA, USA) for 24h. Cells were then stimulated with
or without HRG b1 (R&D Systems, Mpls, MN, USA) for 1h. Cell
lysates were immunoprecipitated as described above using the
polyclonal antibody to Ebp1. Western blot analysis was performed
using a monoclonal antibody to AR (Santa Cruz) or the Ebp1
antibody.
Luciferase reporter assays
Cells (5 10
4) were plated in 12-well plates in complete media.
When cells reached 50–60% confluence, they were transfected
using the Fugene-6 Reagent (Roche, Indianapolis, IN, USA)
according to the manufacturer’s instructions. Cells were trans-
fected with 0.5mg of the indicated reporter plasmids, 0.5mgo f
pSG5-hAR (where specified), and 0.5mg of pcDNA3 or wild-type
ebp1 expression plasmids and 5ng of the TK-Renilla plasmid
(Promega, Madison, WI, USA) as an internal control. Complete
medium was replaced 24h after transfection with phenol red free
RPMI 1640 with CSS with or without R1881 (10
 8 M) (Sadar and
Gleave, 2000). Luciferase activity was determined using the
Promega Dual luciferase assay kit as described by the manufac-
turer. The levels of luciferase activity were normalised using the
renilla luciferase as an internal control. The ratio of luciferase
activity to the renilla control derived from cells that were
transfected with vector alone and not treated was given a Relative
Luciferase Activity value of 1. All values presented in the individual
figures were derived by comparison to this ratio observed in
control cells. Transfection efficiency was approximately 30% as
judged by parallel experiments using the EGFP-N1 plasmid
(Clontech, Palo Alto, CA, USA). All transfection experiments were
carried out in triplicate wells.
Gene silencing with small interfering RNAs
The siRNA oligonucleotides were purchased from Dharmacon
Research Inc (Lafayette, CO, USA). COS-7 cells were cultured in
12-well plates until 60% confluent. Cells in 1ml of antibiotic-free
culture media were transfected with 60nM final concentration of
annealed oligonucledotides using Lipfectamine 2000 according to
the manufacturer’s instructions. The Ebp1 siRNA sequences
corresponded to the coding regions beginning at nucleotides 476
and 995 (Genbank accession number U87954). The targets
sequences were AAGCGACCAGGAUUAUAUUCU and AAGU-
GAGGUGGAAAGGCGUUU respectively. These sequences do not
match any other human genomic sequences as determined by
BLAST analysis using the NCBI Website. Scrambled oligonucleo-
tides of these sequences were used as negative controls. The
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wild-type AR and the MMTV-luciferase and TK plasmids using
Fugene-6.
Statistical analysis
Results were analysed using a two-tailed Studentst-test. Signifi-
cance was established at Pp0.05.
RESULTS
Ebp1 inhibits transactivation of wild-type AR in prostate
adenocarcinoma cell lines
We previously demonstrated that Ebp1 inhibited transactivation of
the artificial ARE2DS promoter in COS cells transfected with wild-
type AR, and the PSA promoter in LNCaP cells that harbor a
mutant AR (Zhang et al, 2002). We were interested in determining
if Ebp1 represses wild-type AR in prostate cancer cell lines. We
therefore tested the ability of Ebp1 to repress AR-mediated
transcription of the MMTV-luciferase reporter plasmid in andro-
gen-independent DU145 cells transiently transfected with a wild-
type AR and PC-3 AR cells stably transfected with wild-type AR
(Long et al, 2000). Cells were transfected with the MMTV luciferase
reporter construct, ebp1 or the pcDNA vector control, and in the
case of DU145 cells, the expression construct for AR. After 24h, the
cells were stimulated with either R1881 or vehicle for 16h. Cells
were harvested and monitored for dual luciferase activity.
Transfection of ebp1 at 0.5mg per individual well routinely
results in a two- to three-fold increase in Ebp1 expression
levels as determined by Western blot analysis (data not shown).
As expected, R1881 stimulated luciferase activity four- to five-fold
in DU145 and PC-3 AR cells (Figure 1). Ectopic expression of ebp1
reduced AR transactivation to basal levels in both cell types.
Corepressors may have dissimilar effects on the activity of
natural AR regulated promoters due to differential binding of the
AR to androgen response elements within those promoters
(Claessens et al, 2001). We had previously demonstrated that
Ebp1 represses both exogenous and endogenous PSA promoter
activity in LNCaP cells (Zhang et al, 2002). We therefore tested the
ability of Ebp1 to repress the MMTV-luc and probasin native
androgen responsive promoters. LNCaP cells were stimulated with
R1881 and the induction of luciferase activity in the presence and
absence of exogenous ebp1 was measured. Probasin and MMTV
promoters were strongly activated by R1881. AR activation of both
promoters was reduced significantly (Pp0.05) with the ectopic
expression of ebp1 (Figure 2). However, a small but significant
increase in AR activity after R1881 treatment was noted even in the
presence of ebp1.
We next wished to determine if endogenous Ebp1 was important
in AR signalling. COS-7 cells were first transfected with siRNA
targeted to two regions in the Ebp1 cDNA as described in the
Materials and Methods. Cells were then transfected with the AR
expression plasmid, and the MMTV-luciferase reporter construct
the next day. Cells were stimulated with R1881 on day 3 and lysates
collected on day 4. The results of Western blotting experiments
showed that transfection of siRNA directed against Ebp1 reduced
proteins levels about 80% at Day 4 (Figure 3A). This decrease was
not observed in cells transfected with scrambled oligos. Decreased
expression of Ebp1 resulted in a significant (Pp0.05) 3.5-fold
increase in the luciferase activity of the MMTV promoter in the
absence of androgen. No such stimulation was observed in cells
lacking AR. R1881 stimulation of the reporter plasmid was
decreased by inhibition of Ebp1 expression, but this change was
not significant at the Pp0.05 level (Figure 3B). These results
suggest that Ebp1 may be important in repression of AR in the
absence of androgen.
HRG regulates the binding of Ebp1 to ErbB3 and AR
We next determined if ErbB3 could bind Ebp1 in human prostate
cell lines as it does in breast carcinoma cells (Yoo et al, 2000) and if
HRG could affect this binding. Lysates of serum starved LNCaP
cells were incubated with either a mouse monoclonal antibody to
ErbB3 or control IgG. Proteins were resolved by SDS–PAGE and
immunoblotted with antibody to Ebp1. Ebp1 was found in ErbB3,
but not control, immunoprecipitates (Figure 4A). Next, we
determined if the binding of Ebp1 to ErbB3 could be regulated
by HRG. LNCaP cells were serum starved and treated with HRG
(20ngml
 1) for 0, 15, 60 and 120min and 24h. Cell lysates were
immunoprecipitated with antibody to ErbB3 as described. Ebp1
was found in ErbB3 immunoprecipitates of untreated cells
(Figure 4B). There was a decrease in the level of Ebp1 associated
with ErbB3 starting at 15min. No Ebp1 was found in the Erb3
immunoprecipitates 60min after treatment. Binding was increased
2h after treatment and by 24h after HRG treatment, Ebp1 binding
to ErbB3 was restored.
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Figure 1 Ebp1 inhibits the transcriptional activity of the MMTV
promoter in prostate cancer cell lines expressing wild-type AR DU145
(A) or PC3-AR cells (B) were transfected with an MMTV-luciferase
reporter plasmid and pcDNA or pcDNA-ebp1 expression plasmids where
indicated. DU145 cells were also transfected with a wild-type AR
expression plasmid. At 24h after transfection, cells were switched to
phenol-red free RPMI 1640 media with 1% CSS containing R1881 (10
 8 M)
or vehicle control. After 16h, luciferase activity was measured. Each point
represents mean7s.e. of triplicate wells. Representative of three experi-
ments.
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we next determined whether HRG could regulate the association of
endogenous Ebp1 with endogenous AR. LNCaP cells, growing in
complete media, were switched into phenol-red free RPMI 1640
media with 1% CSS and R1881 (10
 8 M) overnight. Cells were then
treated with 20ngml
 1 of HRG b1 for 1h, a time when we could
not detect Ebp1 in ErbB3 immunoprecipitates. Cell lysates were
immunoprecipitated with the Ebp1 antibody. Western blot analysis
of the immunoprecipitates indicated that HRG treatment enhanced
the interaction of Ebp1 with AR (Figure 5A). Examination of cell
lysates revealed that HRG treatment did not increase the level of
AR protein at this 1h time point (Figure 5B).
HRG enhances Ebp1 transcriptional repression. We reasoned
that if HRG could change the association of Ebp1 with AR, it could
affect Ebp1 induced repression of AR transactivation. LNCaP cells
were transiently transfected with the MMTV luciferase reporter
plasmid and limiting amounts of an ebp1 expression construct.
Ebp1 at low concentrations (0.1mg) reduced AR luciferase activity
55%. Maximal inhibition of 90% was observed at 0.5mg of the ebp1
plasmid. This was more than the 80% inhibition previously
observed (Figure 1) and probably due to changes in transfection
efficiencies as different batches of cells and plasmids were used in
these different experiments. Concentrations of HRG (20ngml
 1),
previously demonstrated to increase association of Ebp1 and AR,
significantly (Pp0.05) enhanced Ebp1-mediated repression at low
(0.1 and 0.2mg) amounts of the Ebp1 plasmid (Figure 6).
DISCUSSION
We have previously established that Ebp1, a protein cloned in our
laboratory via its interactions with the ErbB3 receptor, inhibits
AR-mediated transcription and growth of the AR positive LNCaP
cell line (Zhang et al, 2002). In this report, we confirm and extend
our findings by demonstrating that Ebp1 is capable of inhibiting
receptor transactivation independent of cell type or AR target
promoter. In addition, we demonstrate that HRG, the ErbB3
ligand, stimulated the association of Ebp1 with AR and increased
Ebp1 mediated repression of AR activity, providing further
evidence for a link between ErbB ligands and AR function.
This study first demonstrated that Ebp1 inhibition of AR
transactivation was neither promoter nor cell type specific. We had
previously demonstrated that Ebp1 inhibits AR transactivation of
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Figure 2 Ebp1 inhibits transcriptional activity of native AR target
promoters in LNCaP cells. LNCaP cells were transfected with the MMTV
(A) or probasin reporter constructs (B) and 0.5mg of pcDNA3 or the
wild-type ebp1 expression plasmid. At 24h after transfection, cells were
treated with R1881 as described in Figure 1 for an additional 16h and
relative luciferase activity was measured. Each point represents mean7s.e.
of triplicate wells. Representative of two experiments.
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Figure 3 The effect of Ebp1 specific small interfering RNA on
transactivation of AR in COS-7 cells. COS-7 cells were transfected with
scrambled siRNAs (Con) or siRNAs (siRNA) directed towards ebp1
cDNA sequences 476 and 995 using Lipofectamine 2000. The next day the
cells were transfected with the wild-type AR expression plasmid, MMTV-
luc and RL-TK. After 24h, the cells were switched to phenol-red free RPMI
1640 media with 5% CSS with or without R1881. Cell lysates were
harvested for Western blot analysis and luciferase activity 16h later. (A)
The expression of Ebp1 was analysed by Western blotting. Cell lysates
were resolved by SDS–PAGE, proteins transferred onto PVDF mem-
branes and filters blotted with Ebp1 or actin antibodies as indicated. (B)
Effect of Ebp1 siRNA on AR promoter activity. Aliquots of the cells
harvested in (A) were assayed for luciferase activity. Each point represents
mean7s.e. of triplicate wells. Representative of three experiments.
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sthe artificial ARE2 luciferase reporter in COS cells and the PSA
luciferase reporter in LNCaP cells (Zhang et al, 2002). However,
recent studies have demonstrated that AR mediated gene
transcription is influenced by the cell type examined (Kotaja
et al, 2000; Claessens et al, 2001; Holter et al, 2002). For example,
Holter et al (2002) have shown that DAX1 inhibition of PSA and
the ARE2 reporter was more potent in COS-7 than HeLa cells. This
variability has been attributed to the complement of transcription
factors and coregulators in different cell types. Therefore, we
examined AR transactivation of MMTV-luc in two androgen-
independent prostate cancer cell lines, PC3 and DU145, that had
been transfected with wild-type AR. Ebp1 inhibited AR-regulated
transcription in these androgen-independent cells. Similarly,
Cyclin D1 inhibits AR transactivation across a wide variety of
both prostate and nonprostate derived cell lines (Petre-Draviam
et al, 2003). In addition, a number of AR coregulators demonstrate
promoter specificity. For example, ARIP3 enhances transcription
from minimal AREs, yet represses the probasin promoter (Kotaja
et al, 2000). Activation of both the PSA and probasin promoters
requires interactions of the N and C terminal domains of AR, but
this association is not required for activation of MMTV (He et al,
2000). Thus, it was important to examine the effects of Ebp1 on
different native promoters. Here we show that Ebp1 also inhibited
the probasin and MMTV reporters in LNCaP cells as well as PSA as
previously demonstrated (Zhang et al, 2002). Our previous studies
had also shown that inhibition of AR transactivation is specific, as
Ebp1 did not affect the estrogen induced responsiveness of an ERE
luciferase reporter or the thyroid hormone mediated activity of a
TRE luciferase reporter plasmid (Zhang et al, 2002). It is of interest
to note that while ebp1 overexpression completely inhibited AR
activity in DU145 and PC-3 AR transfected cells, ebp1 was unable
to completely suppress the response to R1881 in LNCaP cells. This
discrepancy may have been due to different expression levels of AR
in the DU145 and PC-3 cells lines as compared to LNCaP cells, the
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Figure 4 In vivo interaction of Ebp1 with ErbB3 (A) Ebp1 associates with
ErbB3 in LNCaP cells. LNCaP cell lysates were immunoprecipitated with
mouse isotype control IgG (lane 1) or an anti-ErbB-3 monoclonal antibody
(lane 2) and analysed by sequential immunoblotting (IB) with either Ebp1
(top panel) or ErbB3 (bottom panel) antibodies. (B) HRG-induced
dissociation of Ebp1. LNCaP cells were left untreated (0) or stimulated with
HRG (20ngml
 1) for the times indicated. ErbB-3 associated Ebp1 was
analysed by ErbB-3 immunoprecipitation (IP) and sequential immunoblot-
ting (IB) with antibodies against Ebp1 (top) and ErbB-3 (bottom).
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Figure 5 HRG increases the binding of AR to Ebp1 in LNCaP cells. (A)
LNCaP cells growing in complete media were switched to phenol red free
RMPI 1640 containing 1% CSS and 10
 8 M R1881 overnight. Cells were
then incubated in the absence (Con) or presence of HRG b1 (HRG)
(20ngml
 1) for 1h. Cell lysates were then immunoprecipitated (IP) with
antibody to Ebp1 (Ebp1, lanes 2 and 3) or preimmune IgG (IgG) (lane 4).
Immunoblots (IB) were analysed using a monoclonal antibody to AR
(upper panel) or a polyclonal antibody to Ebp1 (lower panel) as indicated.
IN¼input (5% of total) used for immunoprecipitation (lane 1). IgG
indicates the heavy chain of IgG detected in Ebp1 immunoblots of the Ebp1
immunoprecipitates. (B) Effects of HRG on AR protein levels. Control
(Con) or HRG treated (HRG) LNCaP cells were prepared as described in
(A). Total cell lysates were resolved by SDS–PAGE, proteins transferred
onto PVDF membranes, and Western blot analysis performed using
monoclonal antibodies to AR or actin as indicated.
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Figure 6 HRG enhances Ebp1 mediated repression of the AR promoter
LNCaP cells were transfected with the MMTV-luciferase reporter plasmid
(0.5mg) and an ebp1 expression plasmid or a pcDNA vector control at the
indicated amounts. After 24h, cells were switched to RPMI 1640 phenol-
red free media with 5% CSS and R1881 with or without HRG b1
(20ngml
 1). Cell lysates were assayed for luciferase activity 16h later. The
relative luciferase activity in the absence of R1881 was set at 1 for cells that
received the vector control. All activities presented in the graph were
derived by comparison to that value. Neither HRG nor ebp1 affected
luciferase activity under these basal conditions. Each point represents
mean7s.e. of triplicate wells. Representative of two experiments.
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sfact the AR receptor is mutated in LNCaP cells, or to different
transfection efficiencies of the ebp1 plasmid among the three cell
lines.
Studies using siRNA demonstrated that inhibition of endogen-
ous Ebp1 expression resulted in increased activity of an androgen
regulated reporter construct in the absence of androgens. No such
effect was observed in cells not expressing the AR. Thus, the
increase in promoter activity in the absence of androgens was
mediated via the AR. This finding suggests that Ebp1 may play a
role in inhibition of AR signalling in the presence of no or
extremely low levels of androgens. Ebp1 has the ability to bind
DNA (Zhang and Hamburger, 2004) and histone deacetylases
(Zhang et al, 2003), and we postulate that Ebp1 might reside on AR
regulated promoters in the absence of androgens to inhibit
transcription. ChIP assays to demonstrate Ebp1 occupancy on
AR promoters are underway in the laboratory. The fact that
abolition of Ebp1 protein enhanced basal, but not AR stimulated
transcription, is somewhat puzzling in light of the fact that
overexpression of Ebp1 inhibits R1881 stimulated, but not basal,
transcription of AR regulated genes. It is possible that basal
transcription by AR is so low in unstimulated LNCaP cells that
Ebp1-mediated repression in the absence of androgens may have
gone undetected. Conversely, overexpression of Ebp1 might drive
Ebp1 to AR promoters in the presence of androgens. Ebp1 might
then recruit HDACS, important in AR transcriptional repression
(List et al, 1999), to the promoter to inhibit gene transcription. The
fact that inhibition of expression of Ebp1 leads to increased
transcriptional activation of AR suggests that endogenous Ebp1
may function to regulate AR signalling in prostate cancer cells.
Although Ebp1 was shown to be associated with ErbB3 in breast
cancer cells (Yoo et al, 2000), the interaction of Ebp1 with ErbB3 in
prostate cells had not yet been demonstrated. Here, we determined
that Ebp1 could also bind ErbB3 in LNCaP cells. To the best of our
knowledge, this is the first demonstration of a direct interaction
between ErbB3 and the AR. It is of interest that Bonaccorsi et al
(2004) recently reported the physical association and subcellular
colocalisation of the EGFR with AR in PC3 cells transfected with
the AR. These studies further support the concept that ErbB
receptors and AR interact in vivo.
We then determined the effects of HRG on Ebp1 function. HRG
treatment resulted in dissociation of Ebp1 from the ErbB3 receptor
in LNCaP cells. The present studies also demonstrate that HRG
regulated the interaction of Ebp1 with the AR receptor. First, we
demonstrated that endogenous Ebp1 associated with endogenous
AR in vivo. However, the efficiency of the Ebp1:AR interaction
was relatively low in the absence of HRG. HRG treatment of LNCaP
cells for 1h enhanced the association of Ebp1 with AR in LNCaP
cells. The basis of the increased association of Ebp1 with AR after
HRG treatment is not known. We have found that HRG increases
phosphorylation of Ebp1 in breast cancer cells (Lessor et al, 2000)
and studies are underway in the laboratory to examine if enhanced
phosphorylation of Ebp1 increases its binding to AR. The
intracellular compartment in which AR and Ebp1 interact in
either the presence or absence of HRG is not clear at this time.
Immunofluorescence analysis in our hands indicates that both
Ebp1 and AR are located in the nucleus and the cytoplasm of
LNCaP cells in the absence of HRG and/or R1881 (data not shown).
The fact that HRG enhances the binding of Ebp1 to AR suggests
that in the absence of HRG, Ebp1 may not optimally affect AR
function. Indeed, HRG potentiated the ability of limiting amounts
of Ebp1 to inhibit AR promoter activity. HRG has been previously
shown to inhibit growth of ARþ but not AR  prostate cancer cell
lines (Grasso et al, 1997b; Lyne et al, 1997). Similarly, Abreu-
Martin et al (1999) found that MEKK-1, a downstream mediator of
HRG signalling, induced apoptosis of ARþ, but not AR , prostate
cancer cell lines. We hypothesise that Ebp1 may be one mediator of
the effect of HRG on AR function. In the presence of low
concentrations of HRG, such as has been observed in prostate
cancer tissues (Lyne et al, 1997), the activity of Ebp1 may be
suboptimal, resulting in increased AR signalling. Thus, although
Ebp1 may be present in prostate cancer cells (Xia et al, 2001b), it
may not be fully functional.
In summary, Ebp1 is a potent corepressor of AR with broad
specificity. Ebp1 maintains its corepressor activity independent of
cell type and promoter examined. Thus, Ebp1 joins a small but
growing group of AR corepressors (Culig et al, 2003). The fact that
interactions of Ebp1 and AR were regulated by HRG suggests a link
between the HRG-generated growth inhibitory signals transduced
through the ErbB3 receptor and the AR receptor. Further studies
are needed to characterise the interactions of ErbB3, Ebp1 and AR
in the progression of prostate cancer.
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